reports
Microbot Medical Announces Strategic Collaboration with Stryker Corpor...
Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications HINGHAM, Mass., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain n...
Microbot Medical Secures Third Patent for the LIBERTY® Robotic System ...
Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent a...
Microbot Medical Initiates Search for U.S. Clinical Sites for the LIBE...
Microbot Medical Initiates Search for U.S. Clinical Sites for the LIBERTY® Robotic System HINGHAM, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbot’s Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human clinical trial, which is expecte...
Microbot Medical Achieves Design Freeze of the LIBERTY® Robotic System...
Microbot Medical Achieves Design Freeze of the LIBERTY® Robotic System; Meets Previously Stated Milestone Timeline Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA HINGHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) achieved the design freeze objective for the LIBERTY® Robotic System. This milestone demonstrates the continued progress towards the commercialization of the world’s first fully disposable robotic system. The Company’s ability to reach this milestone within the previously stated timeframe ref...
Microbot Medical Secures Additional Patent for the LIBERTY® Robotic Sy...
Microbot Medical Secures Additional Patent for the LIBERTY® Robotic System in the United States HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property. “We believe that the U.S. is the largest and most significa...
Microbot Medical Secures Patent for LIBERTY® Robotic System in the Uni...
Microbot Medical Secures Patent for LIBERTY® Robotic System in the United States HINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company’s LIBERTY® Robotic System. Globally, the Company now has 45 patents issued/allowed and 24 pending patent applications. “This achievement is yet another meaningful milestone that adds a secure foundation to build our sustainable competitive advantage. This IP allows us to protect our assets globally and ad...
Microbot Medical Secures Patent Allowance in China; Third Global Juris...
Microbot Medical Secures Patent Allowance in China; Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology HINGHAM, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those received earlier this year from Japan and Israel. Globally, the Company now holds a total of 44 patents issued/allowed and 24 pending patent applications. “This lat...
Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Med...
Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies. His areas of expertise include cardiac catheterization, coron...
Microbot Medical Secures Additional Protection for the One & Done Guid...
Microbot Medical Secures Additional Protection for the One & Done Guidewire Technology with another Notice of Patent Allowance HINGHAM, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA). The allowed application covers Microbot’s double guidewire technology that has been granted in Europe, Japan and now Israel. Globally, Microbot Medical holds a total of 42 patents issued/allowed and 2...
Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictio...
Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology HINGHAM, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions. Japan is the second jurisdiction to grant a patent for the ‘One & Done’ guidewire technology and further protects the novel technology the Company is currently developing. “We are advancing our ...
Microbot Medical Announces Successful Outcome of its Discussions with ...
Microbot Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt FDA Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement of First-in-Human Clinical Trial HINGHAM, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review of the Company’s existing pre-clinical data, the FDA’s feedback will allow the Company to apply for a limi...
Microbot Medical Enhances Scientific Advisory Board with World Renowne...
Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders HINGHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a board-certified radiologist with clinical expertise in Interventional Radiology with a focus in Tumor Ablation; Ajay K. Wakhloo, MD PhD FA...
Microbot Medical Announces Positive Results of Additional Animal Feasi...
Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world’s first fully disposable sur...
Microbot Medical Demonstrates Significant Progress in 2020; Outlines A...
Microbot Medical Demonstrates Significant Progress in 2020; Outlines Anticipated Milestones for 2021 HINGHAM, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq CM: MBOT) has concluded 2020 with the achievement of several operating and developmental milestones. The Company believes it is well positioned to leverage and capitalize upon this momentum through 2021, with plans to execute additional developmental, regulatory and clinical goals. Key 2020 Operational and Product Achievements Officially unveiled the LIBERTY™ Robotic System, the world’s first fully disposabl...
Microbot Medical to Share Current Progress and Expected 2021 Milestone...
Microbot Medical to Share Current Progress and Expected 2021 Milestones at Upcoming Conferences HINGHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, CEO, President and Chief Executive Officer, will be presenting virtually at two upcoming investor conferences. Mr. Gadot will review the Company’s recent achievements, current progress and expected 2021 milestones. HCW Wainwright Bioconnect Conference. Mr. Gadot will be participating in a fireside chat (Q&A session) and for those registered for the conference a video will be avai...
Microbot Medical Secures Patents in Multiple Global Jurisdictions
Microbot Medical Secures Patents in Multiple Global Jurisdictions HINGHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company’s continued execution of expanding and protecting its Intellectual Property (IP) portfolio. The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide. “As we continue to make progress on the development, clinical and regulatory fronts, it is encouraging that we are also achieving our goals to broaden the ...
Microbot Medical to Highlight Progress and Recent Achievements at H.C....
Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference Webcast to be Held on Thursday November 12th at 2:00pm ET HINGHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that Harel Gadot, the Company’s CEO, President and Chairman, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright 6th Annual Israel Conference, on November 12, 2020 at 2:00pm ET. In addition to the presentation, the conference will feature virtual one-on-one meetings ...
Microbot Medical Schedules Virtual Meeting to Address Increased Intere...
Microbot Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement Webinar to be Held on Wednesday August 26th at 11am ET HINGHAM, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Following its participation at the Needham Virtual Med Tech & Diagnostic conference, as well as the overwhelming interest generated since its recent announcement which included the outcome of a feasibility animal study with respect to the LIBERTYTM Robotic System, Microbot Medical Inc. (Nasdaq: MBOT) will host a webinar on Wednesday, August 26, 2020 at 11:00am ET. Harel Gadot...
Microbot Medical Announces Successful Animal Study Utilizing Its LIBER...
Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY™ Robotic System World’s First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Remotely Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Contamination to Both the Patients and the Surgical Staff HINGHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), today announced the successful conclusion of its feasibility animal study using the Company’s LIBERTY™ Robotic System, the world’s first fully dis...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.